These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4350685)

  • 41. [Effect of bezafibrate on disorders of lipid metabolism].
    Stryjek-Kamińska D; Ilińska-Debniak K; Bartosiewicz W; Szczepanik Z
    Pol Tyg Lek; 1983 Dec; 38(50):1567-71. PubMed ID: 6379618
    [No Abstract]   [Full Text] [Related]  

  • 42. [Classification of hyperlipoproteinemias].
    Zabel R
    Dermatol Monatsschr; 1974 Feb; 160(2):134-50. PubMed ID: 4369507
    [No Abstract]   [Full Text] [Related]  

  • 43. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
    Nikkilä EA; Ylikahri R; Huttunen JK
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Drug therapy of hyperlipidemias].
    Wolfram G
    Wien Med Wochenschr; 1981; 131(13-14):333-8. PubMed ID: 7281700
    [No Abstract]   [Full Text] [Related]  

  • 45. Hyperlipoproteinemia type IV and pre-beta-lipoprotein. Some new aspects of its physiology, pathogenesis and diagnosis.
    Wille LE
    J Oslo City Hosp; 1972; 22(11):169-84. PubMed ID: 4344735
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment with high-dose beta-pyridylcarbinol: results in patients with hypercholesterinemia].
    Mordasini R; Schlumpf E; Nobile PC; Brun del Re G; Riva G
    Schweiz Med Wochenschr; 1978 Apr; 108(14):533-8. PubMed ID: 635510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Sitosterol in familial hyperlipoproteinemia type II. A randomized double-blind cross-over study].
    Oster P; Schlierf G; Heuck CC; Greten H; Gundert-Remy U; Haase W; Klose G; Nothelfer A; Raetzer H; Schellenberg B; Schmidt-Gayk H
    Dtsch Med Wochenschr; 1976 Sep; 101(36):1308-11. PubMed ID: 182445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Altering lipid patterns in adult males.
    Appelbaum JJ; Amundsen MA; Perkin DK
    J Occup Med; 1974 Aug; 16(8):539-42. PubMed ID: 4367267
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of primary lipoproteinemia type IIa and IIb with highly purified dextro-thyroxine (D-T4). Controlled study in ambulant conditions].
    Klemens UH; von Löwis P
    Dtsch Med Wochenschr; 1974 Mar; 99(11):487-93. PubMed ID: 4365703
    [No Abstract]   [Full Text] [Related]  

  • 51. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A physician's guide to hyperlipidemia.
    Fredrickson DS
    Mod Concepts Cardiovasc Dis; 1972 Jul; 41(7):31-6. PubMed ID: 4343098
    [No Abstract]   [Full Text] [Related]  

  • 53. Colestipol in familial type II hyperlipoproteinemia: a three-year trial.
    Harvengt C; Desager JP
    Clin Pharmacol Ther; 1976 Sep; 20(3):310-4. PubMed ID: 182429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J; Bang HO
    Acta Med Scand; 1976; 200(1-2):55-58. PubMed ID: 183462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Change of lipoprotein pattern by clofibrate in hyperglyceridaemia and mixed hyperlipidaemia.
    Miettinen TA; Penttilä IM; Lampainen E
    Acta Med Scand; 1972 Sep; 192(3):177-82. PubMed ID: 4341290
    [No Abstract]   [Full Text] [Related]  

  • 56. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
    J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
    [No Abstract]   [Full Text] [Related]  

  • 57. Signs of coronary atherosclerosis in apparently healthy men with different types of hyperlipoproteinaemia.
    Olsson AG
    Postgrad Med J; 1975; 51(8):40-3. PubMed ID: 1221379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of hyperlipoproteinaemia type II A with a new anion exchange resin secholex.
    Gustafson A; Lanner A
    Eur J Clin Pharmacol; 1974; 7(1):65-9. PubMed ID: 4369397
    [No Abstract]   [Full Text] [Related]  

  • 59. Secholex, Clofibrate and taurine in hyperlipidaemia.
    Howard AN; Evans RJ
    Atherosclerosis; 1974; 20(1):105-16. PubMed ID: 4376405
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia.
    Carlson LA; Orö L; Ostman J
    Acta Med Scand; 1968 May; 183(5):457-65. PubMed ID: 4883477
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.